A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Abstract Text:

Katharina Slupetzky,Ratish Gambhira,Timothy D Culp,Saeed Shafti-Keramat,Christina Schellenbacher,Neil D Christensen,Richard B S Roden,Reinhard Kirnbauer,

Peptides of the papillomavirus L2 minor capsid protein can induce antibodies (Ab) that neutralize a broad range of human papillomavirus (HPV) genotypes. Unfortunately, L2 is antigenically subdominant to L1 in the virus capsid. To induce a strong anti-L2 Ab response with cross-neutralizing activity to other mucosal types, chimeric virus-like particles (VLP) were generated in which HPV16 L2 neutralization epitopes (comprising L2 residues 69-81 or 108-120) are inserted within an immunodominant surface loop (between residues 133 and 134) of the L1 major capsid protein of bovine papillomavirus type 1 (BPV1). These chimeras self-assembled into pentameric capsomers, or complete VLP similar to wild type (wt) L1 protein. Immunization of rabbits with assembled particle preparations induced L2-specific serum Ab with titers 10-fold higher than those induced by cognate synthetic L2 peptides coupled to KLH. Antisera to both chimeric proteins partially neutralized HPV16 pseudovirions, confirming that both HPV16 L2 peptides define neutralization epitopes. When analyzed for the ability to cross-neutralize infection by authentic HPV11 virions, using detection of early viral RNA by RT-PCR-assays as the readout, immune serum to chimeric protein comprising L2 residues 69-81, but not 108-120, was partially neutralizing. In addition, mouse-antiserum induced by vaccinations with synthetic L2 peptide 108-120, but not 69-81, was partially neutralizing in this assay. Induction of cross-neutralization Ab by L2 epitopes displayed on chimeric VLP represents a possible strategy for the generation of broad-spectrum vaccines to protect against relevant mucosal HPV and associated neoplasia.

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Publishing Authors By Initials

K Slupetzky,R Gambhira,TD Culp,S Shafti-Keramat,C Schellenbacher,ND Christensen,RB Roden,R Kirnbauer,

For similar proteins: recombinant proteins: vaccines, synthetic: vaccines, virosome research abstracts see: proteins: recombinant proteins: vaccines, synthetic: vaccines, virosome research

PUBMED ID PMID:

MEDLINE DATE:

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Vaccine

VOLUME: 25

Page Numbers: 2001-10

Journal Abbreviation: Vaccine

ISSN: 0264-410X

DAY: 29

MONTH: 11

YEAR: 2006

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8406899

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Keywords Mesh Terms:

KEYWORDS: Vaccines, Virosome

MESH TERMS: immunology

Chemical & Substance for Abstract: A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Information

Substance Name: Vaccines, Virosome

Registry Number: 0

Grant and Affiliation Information for A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

AFFILIATION: Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Country: Netherlands

AGENCY: United States NCI

GRANT: P50 CA098252

ACRONYM: CA

MEDLINETA: Vaccine

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A papillomavirus-like particle VLP vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11 Related Publications

• A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
• A subset of equine sarcoids harbours BPV-1 DNA in a complex with L1 major capsid protein.
• Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.
• Regression of deeply infiltrating giant condyloma (Buschke-Löwenstein tumor) following long-term intralesional interferon alfa therapy.